Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 5/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764555 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3CETPNR1H2 | |
| SCHEMBL9885645 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3CETPNR1H2 | |
| SCHEMBL13845643 | 0.91 | CHRM2 (0.42) | CHRM2CHRM1CHRM3CETPNR1H2 | |
| SCHEMBL24509252 | 0.85 | CHRM2 (0.45) | CHRM2CHRM1CHRM3CETPNR1H2 | |
| SCHEMBL14319916 | 0.85 | CHRM2 (0.47) | CHRM2CHRM1CHRM3CETPNR1H2 | |
| SCHEMBL3942600 | 0.84 | CETP (0.58) | CETPNR1H2ABCB1 | |
| SCHEMBL13609119 | 0.84 | CETP (0.58) | CETPNR1H2ABCB1 | |
| SCHEMBL12178814 | 0.82 | CHRM2 (0.51) | CHRM2CHRM1CHRM3CETPNR1H2 | |
| SCHEMBL759059 | 0.81 | CETP (0.44) | CHRM2CHRM1CHRM3CETPNR1H2 | |
| SCHEMBL4071602 | 0.81 | CETP (0.44) | CHRM2CHRM1CHRM3CETPNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463282-B1 | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | NOVARTIS AG (CH) | 2013-08-07 | — | — | EP | disclosed |
| US-8440682-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8420641-B2 | Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20120264773-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120208816-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2463282-A1 | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-8193349-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| EP-2207775-B1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2207775-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | Novartis Ag (CH) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264773-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CHRM2 1620/4885CHRM1 907/4885CHRM3 2224/4885 |
| US-20090118287-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CHRM2 1620/4885CHRM1 907/4885CHRM3 2224/4885 |
| US-20120208816-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CHRM2 1620/4885CHRM1 907/4885CHRM3 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.